Media Coverage

Genomic Vision (Paris:GV) (FR0011799907 - GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced its revenue and cash position1 at March 31, 2019. First quarter 2019 revenue In € thousands Q1 2019 Q1 2018 Revenue from R&D collaboration with Quest Diagnostics 75 75 Sales of products and

With the recent formation of the Get the Medications Right (GTMRx) Institute, Quest Diagnostics and the other institute co-founders aim to drive the use of advanced diagnostics for guiding patient treatment.[CR-LF][CR-LF]Launched this month by organizations including J&J, Medecision, and the American College of Clinical Pharmacy, the institute will function "as an advocacy entity" for companion diagnostics and pharmacogenomic testing, said Steve Goldberg, vice president, medical affairs, population health and chief health officer, health and wellness at Quest, and a member of the GTMRx board.

Changes in state laws regarding the treatment of marijuana, which are in direct conflict with federal law, have raised concerns and caused confusion among employers and employees regarding standards for drug-free workplaces and employment drug testing procedures and programs. An Arizona US District Judge is the latest to weigh in on the matter—ruling on the side of a Walmart worker who had been fired after failing a company drug test.[CR-LF][CR-LF]US employers are feeling the impact of liberalized marijuana laws, according to employment drug testing performed by Quest Diagnostics, a leading provider of diagnostic information services.

One day after the Texas House overwhelmingly voted to virtually decriminalize the possession of small amounts of marijuana for first-time offenders, the president of the Texas Senate effectively drove a stake through the heart of the measure.[CR-LF][CR-LF]"I join with those House Republicans who oppose this step toward legalization of marijuana," Lt. Gov. Dan Patrick said in a tweet Tuesday morning. Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

An alliance of independent health systems across Massachusetts has expanded from three to 10 organizations, enabling them to leverage cheaper contracts while maintaining their autonomy.[CR-LF][CR-LF]The Massachusetts Value Alliance, which initially formed in 2016, is a collaboration of 14 hospitals in the state that work together on group purchasing contracts and share best practices in order to be competitive in their market while still remaining independent. The combined health systems serve about 2 million people. Since the Massachusetts alliance formed three years ago, the organizations have worked together to negotiate on lab referral contracts. The members waited until their contracts were up and decided to go forward with one contract with Quest Diagnostics.

More U.S. workers are testing positive for marijuana while the number testing positive for opioids continues to decline, according to the annual Quest Diagnostics Drug Testing Index.[CR-LF][CR-LF]Based on an analysis of nine million drug tests conducted in 2018, Quest determined that 5.1 percent of the general workforce tested positive for drugs and another 2.7 percent of workers in safety-sensitive positions regulated by federal law did so. Those in safety-sensitive jobs include pilots; rail, bus and truck drivers; and workers in nuclear power plants.

As hospitals turn to technology to overhaul the patient experience and improve profits, a range of vendors from are bring new products and outsourced services to meet that demand with artificial intelligence, data analytics and natural language processing as well as cognitive and process automation.The end-to-end solution may not work for every system, but all providers are looking to modernize. Some do it through Optum products such as computer assisted coding technologies with natural language processing baked in.[CR-LF][CR-LF]Using partner Quest Diagnostics, Optum360 can predict patient responsibility at the point of service.

As attorneys argued over a section of an Arizona law that differentiates between marijuana and cannabis, the state’s Supreme Court justices joked about baking pot brownies in their kitchens.[CR-LF][CR-LF]They clearly do not understand how the marijuana industry has irresponsibly manipulated pot into dangerously high levels of potency.[CR-LF]Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

Major testing lab Quest Diagnostics says a small proportion of workforce tests nationally come back positive for marijuana or any other drugs, but the number has been growing in recent years.[CR-LF][CR-LF]Including job applicants and hired workers, the positive-test rate for marijuana was 2.8% last year, up from 2.4% in 2014, the Secaucus, New Jersey-based company said Thursday.

UnitedHealthcare this week named seven labs to its new Preferred Laboratory Network. They are AmeriPath/DermPath, a division of Quest Diagnostics; BioReference and its GeneDx lab; Invitae; Laboratory Corporation of America; Mayo Clinic Laboratories; and Quest. PLN's goal is threefold: to make healthcare affordable, improve outcomes, and improve the patient experience, UHC said in a statement. PLN launches on July 1, 2019. While UHC customers can choose a lab not in PLN, the price of services accessed through the network will be lower, UHC said, noting that pathology services for a biopsy in PLN would be $90 compared to $150 outside of PLN.

The number of people caught cheating on employer-required drug tests rose by 40% from 2017 to 2018, according to figures compiled by Quest Diagnostics.[CR-LF][CR-LF]"This is common," said Tim Terrill, the owner of ARCPoint Labs of Scottsdale - North.

The number of people caught cheating on employer-required drug tests rose by 40% from 2017 to 2018, according to figures compiled by Quest Diagnostics.

Hasbro, Twitter and Quest Diagnostics were among the best performers of the day. last year, they had the worst trading day ever. s&p 500 is up 17% this year

A simple test using a swab of cells from the inside of your cheek can dramatically improve your medical treatment. The test can predict whether a drug will help, if you need a different dosage, or if you are at risk of severe side effects.[CR-LF][CR-LF]This testing is called pharmacogenetics or pharmacogenomics. This means studying the interactions of drugs (pharma-) and an individual’s genes (genom-). Genes control how drugs are metabolized and may be different in different people. Treatment can be personalized, or individualized for some classes of drugs.[CR-LF][CR-LF]Several companies provide different panels for pharmacogenetic testing. Some are mostly focused on psychiatric drugs, like Myriad Genetics’ (MYGN: Nasdaq) pricey GeneSight test, at $2000. There are the big labs, like LabCorp (NYSE: LH), Quest Diagnostics (NYSE: DGX), Mayo Clinics, and smaller companies which focus only on pharmacogenomics, like Genelex, a private company. In choosing a lab, look at certification, the types of panels of testing that are offered (and whether they include the enzymes metabolizing the drugs you are taking), and the type of explanation they provide you and your physician.

New home sales, the Richmond Fed manufacturing survey, and the FHFA home price index data will surface. JetBlue (JBLU), Quest Diagnostics (DGX), Sherwin-Williams (SHW), Snap (SNAP), TD Ameritrade (AMTD), and Texas Instruments (TXN) are on the earnings schedule.

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2019.[CR-LF][CR-LF]"We're off to a good start in 2019, with solid volume growth from our expanded health plan access," said Steve Rusckowski, Chairman, President and CEO. "As we anticipated, volume accelerated through the quarter, and we look forward to continued progress as a member of UnitedHealthcare's Preferred Lab Network beginning July 1. We continue to drive productivity to address ongoing reimbursement pressure, and are well positioned to meet our financial commitments for the remainder of 2019."

Quest Diagnostics today reported revenues for its first quarter were up a fraction of 1 percent year over year.[CR-LF][CR-LF]For the three months ended March 31, total revenues inched up to $1.89 billion from $1.88 billion in Q1 2018, beating analysts' average estimate of $1.87 billion. Revenues from Diagnostic Information Services grew to $1.81 billion from $1.80 billion.[CR-LF][CR-LF]On a conference call following the release of the results, Quest President, CEO, and Chairman Steve Rusckowsi said that test volume grew almost 4 percent year over year. Key test growth drivers in the quarter included tuberculosis, Cardio IQ, drug monitoring, and hemapathology blood cancer testing, "all of which showed revenue growth" in Q1.

Quest Diagnostics, the world's leading provider of diagnostic information services, launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States. The new STD test packages are the first to be offered directly by Quest Diagnostics or any other major national laboratory to allow individuals to purchase tests at their discretion. These new packages have been designed to meet the needs of individuals who want accurate basic or comprehensive STD testing.[CR-LF][CR-LF]The new services are designed to empower individuals to access STD screening when they are reluctant to engage their healthcare provider directly. Research by Quest Diagnostics shows that patients and healthcare providers often fail to discuss sexual behavior and STD risk. According to a survey commissioned by Quest, 51 percent of females age 18-24 years say they don't want to bring up for discussion the topics of sex or STDs with their clinicians and 49 percent claim their clinician has never asked if they want STD testing.

Shares of Quest Diagnostics (DGX - Get Report) climbed 7.4% to $91.50 Tuesday after the diagnostic testing company reported better-than-expected first-quarter earnings.[CR-LF][CR-LF]The Secaucus, N.J.-based company reported net income of $164 million, or $1.20 a share, down from $177 million, or $1.52 a share, a year ago. Adjusted earnings came to $1.40 a share, surpassing analyst's forecasts of $1.36.[CR-LF][CR-LF]Revenue totaled $1.89 billion, up 0.4% from a year ago, and beat Wall Street's expectation of $1.87 billion. Cash provided by operations was $275 million, up 53.4% from 2018.

Quest Diagnostics (DGX) Q1 results: Revenues: $1,891M (+0.4%).[CR-LF][CR-LF]Net Income: $164M (-7.3%); Non-GAAP Net Income: $190M (-10.0%); EPS: $1.20 (-5.5%); Non-GAAP EPS: $1.40 (-7.9%); CF Ops: $275M (+52.8%).[CR-LF][CR-LF]2019 Guidance: Revenues: $7.6B - $7.75B (unch); EPS: >$5.16 (unch); Non-GAAP EPS: >$6.40 (unch); CF Ops: ~$1.3B (unch).[CR-LF][CR-LF]The consensus Revenue and GAAP EPS estimate was $1.87B and $1.38, respectively.

Quest Diagnostics (NYSE:DGX): Q1 Non-GAAP EPS of $1.40 beats by $0.02; GAAP EPS of $1.20. Revenue of $1.89B (+0.5% Y/Y) beats by $20M.

Tuesday morning's results are the first Quest has shared since getting back into the UnitedHealth network at the start of the year. The agreement with UnitedHealth has given Quest access to more patient lives than at any time in the past decade. Accordingly, organic requisition volume growth was up 2.4%, compared to 1.1% in the fourth quarter of 2018, and would have been around 3% if headwinds including a slightly shorter quarter were excluded.

Accurate estimates of non-alcoholic steatohepatitis (NASH) prevalence are lacking, particularly the subset of patients with advanced fibrosis. We aim to evaluate prevalence and predictors of advanced fibrosis among patients with probable NASH using national clinical laboratory data. Clinical laboratory data from October 1, 2017-September 30, 2018 were collected using Quest Diagnostics database, which tests ∼30% of U.S. adults annually. Adults with negative hepatitis B surface antigen, negative hepatitis C antibody, and elevated alanine aminotransferase (ALT) (>25 U/L women, >35 U/L men) were evaluated for prevalence of ≥F 3 fibrosis using fibrosis-4 score (FIB-4)>2.67.

Women's healthcare is historically no fun. I mean, the process of a pap smear speaks for itself. Thankfully, it seems many women feel this way, and some particularly driven women decided to do something about it.[CR-LF][CR-LF]A handful of companies took the most inconvenient and awkward aspects of women's health — like a trip to the gynecologist just for a prescription refill, or checking out at CVS with condoms — and made them much easier.[CR-LF][CR-LF]Modern Fertility emphasizes the convenience and price tag of its products -- no commute or clinic visit, and no sticker shock. You can take your test at home, or opt to take it at a Quest Diagnostics lab if there's one near you.

In the United States, more than 178 million Americans receive insurance coverage through an employer; of these, approximately 60% have insurance from a self-insured employer. Healthcare costs, both medical and pharmacy, for employers and employees continue to increase at a 6% predicted rate in 2019, on top of the 5 to 6 percent annual increases observed since 2014. The increase in healthcare spending has been directly attributed to increased prices for healthcare services, while utilization has remained somewhat consistent. Today we’re speaking with Dr Steven Goldberg, the vice president of medical affairs, population health, and chief health officer at Quest Diagnostics. He is also a co-author of a recent peer-reviewed case study that analyzed a benefits and wellness program designed by a self-insured employer.